GENFIT's G1090N Shows Promising Phase 1 Results for Acute-on-Chronic Liver Failure Treatment
核心洞察
GENFIT's investigational drug G1090N demonstrated a favorable safety and tolerability profile in Phase 1 trials with 76 healthy volunteers, supporting continued clinical development for acute-on-chronic liver failure.
Ex vivo studies revealed strong anti-inflammatory activity, with G1090N showing up to 76% statistically significant inhibition of pro-inflammatory cytokines in blood samples from study participants.
The company plans to advance G1090N into Phase 2 proof-of-concept studies after engaging with regulatory authorities including the FDA, targeting a condition with no approved therapies.
GENFIT announced positive Phase 1 results for G1090N, its lead investigational drug candidate for acute-on-chronic liver failure (ACLF), demonstrating both favorable safety profile and compelling anti-inflammatory activity. The findings position the small molecule as a promising therapeutic option for a condition with no approved treatments and significant unmet medical need.
Phase 1 Safety and Tolerability Results
The Phase 1 open-label trial evaluated G1090N's safety, tolerability, and pharmacokinetics in healthy volunteers through both Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) phases. A total of 76 participants were enrolled, with 13 healthy volunteers in each segment. The study confirmed that G1090N has a favorable safety profile that supports continued clinical evaluation.
Dr. Jacqueline O'Leary at UT Southwestern Medical Center (搜索) commented on the significance of these findings: "The safety profile observed in Phase 1 and the consistent biological activity evidenced in ex vivo assays represent a meaningful step in development. These findings position G1090N as a promising candidate for patients with acute decompensation and for patients with ACLF, a life-threatening condition with no approved therapies and significant unmet medical need."
Strong Anti-Inflammatory Activity Demonstrated
GENFIT conducted comprehensive ex vivo pharmacodynamic and proof-of-efficacy assays to evaluate G1090N's modulation of inflammation-related signaling pathways. The results revealed robust biological activity in peripheral blood mononuclear cells (PBMC) assays from healthy volunteers, using blood samples from Phase 1 study participants.
The drug demonstrated up to 76% statistically significant inhibition (p<0.0001) of LPS-induced IL-6 and TNFα (搜索) cytokines production. Additionally, the bioactive metabolite of G1090N confirmed its anti-inflammatory potential in ex vivo assays performed on blood collected from cirrhotic donors.
These findings indicate that G1090N displays strong anti-inflammatory activity at the doses tested in the first-in-human study, effectively engages its target mechanism of action in circulating immune cells, and modulates key pathways driving systemic inflammation—a major contributor to acute decompensated cirrhosis with or without ACLF.
Addressing Critical Unmet Medical Need
ACLF represents a rapid and severe worsening in individuals with chronic liver disease or cirrhosis, marked by acute hepatic decompensation and failure of one or more extrahepatic organs, leading to significant morbidity and mortality. The condition remains a significant unmet medical need, with no approved therapies and minimal benefits from existing lifestyle-focused interventions.
This multifactorial syndrome often develops in patients with underlying liver disorders such as alcohol-associated liver disease, drug-induced liver injury, or viral hepatitis. The absence of targeted pharmacological options underscores a substantial therapeutic void, presenting a compelling opportunity for pharmaceutical innovation.
Limited Competitive Landscape
The ACLF drug development landscape remains narrow, with only a handful of companies actively advancing therapies. GENFIT leads the field with four assets in its R&D pipeline, including programs currently in Phase 2. Beyond G1090N, the company's candidates include VS-01, SRT-015, CLM-022, and VS-02-HE, all based on differentiated mechanisms of action leveraging complementary pathways.
Other notable ACLF candidates in clinical trials include YAQ005 (搜索) from Yaqrit (搜索) and ALBUTEINE (搜索) (albumin 5%) from Grifols Therapeutics (搜索). Grifols' Albumin 5% is currently being investigated in the Phase III APACHE clinical trial, evaluating the effect of plasma exchange with 5% human serum albumin on short-term survival in high-risk ACLF patients.
Next Steps and Regulatory Strategy
Based on these positive Phase 1 results, GENFIT plans to engage with regulatory authorities, including the U.S. Food and Drug Administration, to determine the best approach for progressing to Phase 2 proof-of-concept studies in inflammatory conditions such as ACLF where systemic immune dysregulation is a critical driver of disease progression.
The company's focus on ACLF and associated conditions such as acute decompensation and hepatic encephalopathy represents part of its broader commitment to improving the lives of patients with rare, life-threatening liver diseases. GENFIT's expertise in developing high-potential molecules culminated in 2024 with the accelerated approval of Iqirvo® (elafibranor) by the FDA, EMA, and MHRA for primary biliary cholangitis treatment.
Developers of the first approved therapies for ACLF stand to gain early-mover advantages, including regulatory incentives, enhanced physician adoption, and favorable market positioning. Given the condition's progressive nature and high morbidity, there is strong justification for expedited drug development and regulatory acceleration to bring effective, targeted treatments to patients sooner.